Firestein B L, Xing M, Hughes R J, Corvera C U, Insel P A
Department of Pharmacology, School of Medicine, University of California at San Diego, La Jolla 92093-0636, USA.
Am J Physiol. 1996 Sep;271(3 Pt 2):F610-8. doi: 10.1152/ajprenal.1996.271.3.F610.
We have characterized the signaling pathways of purinergic receptors present on the renal epithelial cell line, Madin-Darby canine kidney (MDCK, D1 subclone). Several lines of evidence are consistent with the conclusion that coexisting P2u and P2y receptors release arachidonic acid and metabolites (AA) from MDCK-D1 cells: 1) relative potencies of nucleotide analogues, 2) blockade of P2y agonist- but not P2u agonist-mediated release by suramin, and 3) additivity by 2-methylthio-ATP and UTP. Differences exist between the signaling pathways of the two receptors: pertussis toxin treatment partially inhibits P2u- but not P2y-mediated AA release, and P2y (but not P2u) receptors appear to stimulate D-myo-inositol 1,4,5-trisphosphate production. P2u-receptor occupancy results in both homologous and heterologous desensitization; P2y-receptor occupancy elicits only homologous desensitization. Both receptors stimulate phosphatidylcholine hydrolysis via phospholipase C activation. However, AA release appears to result from phospholipid deacylation by phospholipase A2 activation, rather than from alternate pathways that may include PLC activation. These results demonstrate for the first time that two subtypes of P2-purinergic receptors, P2u and P2y receptors, coexist on a single renal epithelium cell type and that these two receptor subtypes can promote AA release, probably via activation of PLA2.
我们已经对肾上皮细胞系——Madin-Darby犬肾(MDCK,D1亚克隆)上存在的嘌呤能受体的信号通路进行了表征。几条证据支持以下结论:共存的P2u和P2y受体从MDCK-D1细胞释放花生四烯酸及其代谢产物(AA):1)核苷酸类似物的相对效力;2)苏拉明阻断P2y激动剂介导而非P2u激动剂介导的释放;3)2-甲硫基-ATP和UTP的相加作用。两种受体的信号通路存在差异:百日咳毒素处理部分抑制P2u介导而非P2y介导的AA释放,且P2y(而非P2u)受体似乎刺激D-肌醇1,4,5-三磷酸的产生。P2u受体占据导致同源和异源脱敏;P2y受体占据仅引发同源脱敏。两种受体均通过磷脂酶C激活刺激磷脂酰胆碱水解。然而,AA释放似乎是由磷脂酶A2激活导致的磷脂脱酰基作用引起的,而非可能包括PLC激活的其他途径。这些结果首次证明,两种P2嘌呤能受体亚型,即P2u和P2y受体,共存于单一类型的肾上皮细胞上,并且这两种受体亚型可能通过激活PLA2促进AA释放。